All In Biotech

Drug Trial Radar · NCT06297603

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 341 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

341

Actual

Start

Mar 15, 2024

Primary completion

Oct 26, 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Mar 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

Conditions

  • Type 2 Diabetes

Interventions

  • RetatrutideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Hemoglobin A1c (HbA1c) (%)Time frame: Baseline, Week 52

Locations

76 sites in 7 countries. Site status is shown where the registry gives one.

  • Nephrology Consultants

    Huntsville, Alabama

  • Clinical Research Institute of Arizona (CRI) - Sun City West

    Sun City West, Arizona

  • Kidney & Hypertension Center - Apple Valley

    Apple Valley, California

  • Hope Clinical Research, Inc.

    Canoga Park, California

  • Neighborhood Healthcare Institute of Health

    Escondido, California

  • EndoTrials Center for Clinical Research

    La Mesa, California

  • UCLA South Bay Endocrinology

    Torrance, California

  • Northeast Research Institute (NERI)

    Fleming Island, Florida

  • Encore Medical Research - Weston

    Weston, Florida

  • Orita Clinical Research

    Decatur, Georgia

  • CARE Institute

    Idaho Falls, Idaho

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas

  • Billings Clinic

    Billings, Montana

  • Excel Clinical Research, LLC

    Las Vegas, Nevada

  • Albany Medical College, Division of Community Endocrinology

    Albany, New York

  • NYC Research INC

    Long Island City, New York

  • Research Foundation of SUNY - University of Buffalo

    Williamsville, New York

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina

  • Central States Research

    Tulsa, Oklahoma

  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair

    Pittsburgh, Pennsylvania

  • AM Diabetes & Endocrinology Center

    Bartlett, Tennessee

  • Velocity Clinical Research, Dallas

    Dallas, Texas

  • Prime Revival Research Institute, LLC

    Flower Mound, Texas

  • Juno Research

    Houston, Texas

  • PlanIt Research, PLLC

    Houston, Texas

  • Southern Endocrinology Associates

    Mesquite, Texas

  • Texas Valley Clinical Research

    Weslaco, Texas

  • Diabetes & Endocrine Treatment Specialists

    Sandy City, Utah

  • Investigaciones Medicas Imoba Srl

    Buenos Aires, Argentina

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, Argentina

  • CIPREC

    Buenos Aires, Argentina

  • CIPREC

    Buenos Aires, Argentina

  • Centro Médico Viamonte

    Buenos Aires, Argentina

  • Mautalen Salud e Investigación

    Buenos Aires, Argentina

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, Argentina

  • CEDIC

    CABA, Argentina

  • Centro Diabetológico Dr. Waitman

    Córdoba, Argentina

  • Centro Médico Colón

    Córdoba, Argentina

  • Centro de Investigaciones Clínicas Baigorria

    Granadero Baigorria, Argentina

  • CIMeL

    Lanus, Argentina

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.